Good
Partially Aligned
Patient Risk:
Moderate
Summary
Several elements align with the provided label text (5.1 and 17.1), but the overall set of claims includes multiple quantitative/statistical and mechanistic statements that are not supported by the supplied prescribing information excerpt.
Category Scores
Accurate Statements
Myopathy should be considered in patients with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK, and patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness.
Label section 5.1 Skeletal Muscle: “Myopathy should be considered…” and “Patients should be advised to report promptly…”
LIPITOR therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.
Label section 5.1 Skeletal Muscle: “LIPITOR therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.”
LIPITOR therapy should be temporarily withheld or discontinued in patients with an acute serious condition suggestive of myopathy or having a risk factor predisposing to renal failure secondary to rhabdomyolysis.
Label section 5.1 Skeletal Muscle: “LIPITOR therapy should be temporarily withheld or discontinued…” and examples of risk factors.
Risk of myopathy/rhabdomyolysis is increased with concomitant administration of certain interacting drugs (e.g., cyclosporine and strong CYP3A4 inhibitors such as clarithromycin, itraconazole, and HIV protease inhibitors) and with lipid-modifying doses of niacin, erythromycin, fibric acid derivatives, and azole antifungals.
Label section 5.1 Skeletal Muscle: “concomitant use of higher doses… with certain drugs… increases the risk…” and “risk of myopathy… increased with concurrent administration of…” plus examples.
All patients starting therapy with LIPITOR should be advised of the risk of myopathy and told to report promptly unexplained muscle pain, tenderness, or weakness.
Label section 17.1 Muscle Pain: “All patients starting therapy… should be advised…”
Unsupported Statements
Higher doses of atorvastatin increase the chance and intensity of muscle aches.
The excerpt states increased risk of myopathy/rhabdomyolysis with “higher doses” in the context of concomitant use with certain drugs, but does not support a general statement that higher doses increase chance and intensity of muscle aches across all situations.
Patients taking 80 mg atorvastatin report muscle symptoms more often than those on 10 mg or 20 mg.
No comparative frequency data by dose (10/20/80 mg) is provided in the supplied label excerpt.
About 5–10% of people on any statin dose experience muscle symptoms.
No incidence range is provided in the supplied label excerpt.
Muscle symptom rates are higher with 40 mg and 80 mg atorvastatin regimens.
No regimen-specific rates for 40 mg and 80 mg are provided in the supplied label excerpt.
Muscle symptom rates with 40 mg and 80 mg regimens can reach 15% or more.
No quantitative rate statements (e.g., reaching 15%+) are provided in the supplied label excerpt.
Most patients find relief within days to weeks after switching to a lower dose of atorvastatin or a different statin.
No time-to-relief information or proportion of patients achieving relief is provided in the supplied label excerpt.
Some patients continue the same atorvastatin dose with added coenzyme Q10.
The supplied label excerpt does not mention coenzyme Q10.
Evidence for adding coenzyme Q10 to atorvastatin is mixed.
No coenzyme Q10 discussion is present in the supplied label excerpt.
Muscle pain paired with dark urine can point to rhabdomyolysis.
The supplied label excerpt does not list “dark urine” as a symptom indicator for rhabdomyolysis.
Rhabdomyolysis is a rare but serious complication of statins.
While the excerpt refers to “Rare cases of rhabdomyolysis,” the statement broadens to “of statins” beyond the label text and adds phrasing not explicitly supported as written.
Rhabdomyolysis is more frequent at higher doses.
The excerpt discusses increased risk with certain interacting drugs and mentions higher-dose context in drug interaction, but does not provide a clear dose-response frequency statement for rhabdomyolysis alone.
Many people reach cholesterol goals on 10–20 mg atorvastatin without muscle issues.
The supplied label excerpt does not provide cholesterol-goal achievement rates by dose or directly tie them to muscle symptom occurrence.
If higher doses are needed, doctors may switch to rosuvastatin or pitavastatin.
The supplied label excerpt does not mention rosuvastatin or pitavastatin as alternatives.
If higher doses are needed, doctors may add ezetimibe to keep the statin dose lower.
The supplied label excerpt does not mention ezetimibe or strategies involving dose-lowering with ezetimibe.
The exact cause of statin-related muscle pain is not fully known.
No statement about “exact cause” or knowledge gaps is provided in the supplied label excerpt.
Higher statin levels appear to impair muscle cell energy production.
No mechanistic claim about muscle cell energy production or impairment is provided in the supplied label excerpt.
The effect on muscle cell energy production is dose-dependent.
No mechanistic dose-dependent effect related to muscle cell energy production is provided in the supplied label excerpt.
Contradictions
Important Omissions
Specific guidance that interacting agents may require dose limits (e.g., cyclosporine: “Do not exceed 10 mg atorvastatin daily”; caution when exceeding doses >20 mg with clarithromycin/itraconazole/HIV protease inhibitors) and recommends lower starting/maintenance doses and careful monitoring during initial months and upward titration.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several core safety communications (report promptly unexplained muscle symptoms; discontinue/suspend when myopathy suspected or acute serious risk conditions occur; increased risk with specific interacting drugs) are supported. However, multiple quantitative and mechanistic statements are not supported by the provided label excerpt and could mislead users about incidence rates, timeline of improvement, symptom indicators (e.g., dark urine), and alternative management strategies.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Many claims include unsupported quantitative/statistical incidence estimates, symptom-to-diagnosis mappings, mechanistic explanations, and alternative medication/adjunct strategies that are not present in the supplied label excerpt.
Suggested Improvement
Limit claims to the supported label elements in sections 5.1 and 17.1: risk increase with specific interacting drugs and certain higher-dose contexts, patient counseling to report unexplained muscle symptoms, and instructions to discontinue or temporarily withhold LIPITOR when myopathy is suspected/diagnosed or when acute serious conditions/risk factors for rhabdomyolysis-related renal failure occur; avoid unsupported dose-frequency percentages and non-labeled adjunct/alternative drug suggestions.